comparemela.com

Latest Breaking News On - Mary kwok - Page 1 : comparemela.com

FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma

The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.